Literature DB >> 2021551

Distribution of tamoxifen and metabolites into brain tissue and brain metastases in breast cancer patients.

E A Lien1, K Wester, P E Lønning, E Solheim, P M Ueland.   

Abstract

We determined the amount of tamoxifen, N-desmethyltamoxifen (metabolite X), N-desdimethyltamoxifen (metabolite Z), and hydroxylated metabolites (Y, B, BX) in brain metastases from breast cancer and in the surrounding brain tissues. Specimens were collected from the breast cancer patients who received tamoxifen for 7-180 days and with the last dose taken within 28 h before surgical removal of the tumour. The concentrations of tamoxifen and its metabolites were up to 46-fold higher in the brain metastatic tumour and brain tissue than in serum. Metabolite X was the most abundant species followed by tamoxifen and metabolite Z. Small but significant amounts of the hydroxylated metabolites, trans-1(4-beta-hydroxyethoxyphenyl)-1,2-diphenylbut-1-ene (metabolite Y), 4-hydroxytamoxifen (metabolite B) and 4-hydroxy-N-desmethyltamoxifen (metabolite BX) were detected in most specimens. The ratios between the concentrations of tamoxifen and various metabolites were similar in tumour, brain and serum. This is the first report on the distribution of tamoxifen and metabolites into human brain and brain tumour, and the data form a basis for further investigation into the therapeutic effects of tamoxifen on brain metastases from breast cancer.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2021551      PMCID: PMC1972343          DOI: 10.1038/bjc.1991.147

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  33 in total

1.  METASTATIC BRAIN TUMORS. RESULTS OF SURGICAL AND NONSURGICAL TREATMENT.

Authors:  E F LANG; J SLATER
Journal:  Surg Clin North Am       Date:  1964-06       Impact factor: 2.741

2.  Tamoxifen-induced regression of cerebral metastases in breast carcinoma.

Authors:  R W Carey; J M Davis; N T Zervas
Journal:  Cancer Treat Rep       Date:  1981 Sep-Oct

3.  Effect of bromocriptine on brain metastasis in breast cancer.

Authors:  F Grisoli; F Vincentelli; J Foa; G Lavail; G Salamon
Journal:  Lancet       Date:  1981-10-03       Impact factor: 79.321

4.  Central nervous system metastasis from breast carcinoma. Autopsy study.

Authors:  Y Tsukada; A Fouad; J W Pickren; W W Lane
Journal:  Cancer       Date:  1983-12-15       Impact factor: 6.860

5.  Brain metastases from breast cancer: clinical course, prognosis and influence of treatment.

Authors:  G E Sparrow; R D Rubens
Journal:  Clin Oncol       Date:  1981-12

6.  How long does chlorpromazine last?

Authors:  R B Lacoursiere; H E Spohn
Journal:  J Nerv Ment Dis       Date:  1976-10       Impact factor: 2.254

7.  Tamoxifen antiestrogens. A comparison of the activity, pharmacokinetics, and metabolic activation of the cis and trans isomers of tamoxifen.

Authors:  D W Robertson; J A Katzenellenbogen; D J Long; E A Rorke; B S Katzenellenbogen
Journal:  J Steroid Biochem       Date:  1982-01       Impact factor: 4.292

8.  Systemic chemotherapy for a primary germ cell tumor of the brain: a pharmacokinetic study.

Authors:  S Ginsberg; J Kirshner; S Reich; L Panasci; T Finkelstein; S Fandrich; A Fitzpatrick; L Shechtman; R Comis
Journal:  Cancer Treat Rep       Date:  1981 May-Jun

9.  The distribution and metabolism of 14C-labelled tamoxifen in spayed female mice.

Authors:  N Wilking; L E Appelgren; K Carlström; A Pousette; N O Theve
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1982-03

10.  Intracerebral metastases in solid-tumor patients: natural history and results of treatment.

Authors:  S Zimm; G L Wampler; D Stablein; T Hazra; H F Young
Journal:  Cancer       Date:  1981-07-15       Impact factor: 6.860

View more
  50 in total

Review 1.  Treatment of brain metastases: chemotherapy.

Authors:  Sean A Grimm
Journal:  Curr Oncol Rep       Date:  2012-02       Impact factor: 5.075

Review 2.  Clinical pharmacokinetics of aromatase inhibitors and inactivators.

Authors:  Per Lønning
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

3.  Serum elimination half-life of tamoxifen and its metabolites in patients with advanced breast cancer.

Authors:  D de Vos; P H Slee; D Stevenson; R J Briggs
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

Review 4.  Clinical pharmacokinetics of endocrine agents used in advanced breast cancer.

Authors:  P E Lønning; E A Lien; S Lundgren; S Kvinnsland
Journal:  Clin Pharmacokinet       Date:  1992-05       Impact factor: 6.447

5.  Durable clinical benefit with exemestane in leptomeningeal metastasis of breast cancer.

Authors:  Luis Miguel Navarro Martín; Alberto Ocaña Fernández; Cesar Augusto Rodríguez Sánchez; Isabel Ruiz Martín; Juan Jesús Cruz Hernández
Journal:  Clin Transl Oncol       Date:  2005-09       Impact factor: 3.405

Review 6.  Tamoxifen and amphetamine abuse: Are there therapeutic possibilities?

Authors:  Sarah Mikelman; Natalie Mardirossian; Margaret E Gnegy
Journal:  J Chem Neuroanat       Date:  2016-08-30       Impact factor: 3.052

Review 7.  Optimal management of brain metastases from breast cancer. Issues and considerations.

Authors:  Rupert Bartsch; Anna S Berghoff; Matthias Preusser
Journal:  CNS Drugs       Date:  2013-02       Impact factor: 5.749

8.  Direct and Systemic Administration of a CNS-Permeant Tamoxifen Analog Reduces Amphetamine-Induced Dopamine Release and Reinforcing Effects.

Authors:  Colleen Carpenter; Alexander G Zestos; Rachel Altshuler; Roderick J Sorenson; Bipasha Guptaroy; Hollis D Showalter; Robert T Kennedy; Emily Jutkiewicz; Margaret E Gnegy
Journal:  Neuropsychopharmacology       Date:  2017-05-11       Impact factor: 7.853

9.  MEK1/2 inhibition suppresses tamoxifen toxicity on CNS glial progenitor cells.

Authors:  Hsing-Yu Chen; Yin Miranda Yang; Ruolan Han; Mark Noble
Journal:  J Neurosci       Date:  2013-09-18       Impact factor: 6.167

Review 10.  A critique of the role of the blood-brain barrier in the chemotherapy of human brain tumors.

Authors:  D J Stewart
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.